Stephens Consulting’s West Pharmaceutical WST Stock Holding History

Stephens Consulting’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2	Closed	-$438	–	1183
2025 Q2	$438	Buy	+2	New	+$428	﹤0.01%	933

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return

Stephens Consulting's WST Position: Q3 2025 in Review

Stephens Consulting sold out of West Pharmaceutical (WST) in Q3 2025, closing a stake of 2 shares — an estimated $438 sold.

Stephens Consulting first reported a position in WST in Q2 2025 and held it in 1 quarter. The position peaked at $438 in Q2 2025. 758 funds tracked by Wall St. Rank hold WST as of Q3 2025.

Stephens Consulting reported no remaining West Pharmaceutical position as of Q3 2025 after selling out during the quarter.
Stephens Consulting sold 2 West Pharmaceutical shares in Q3 2025, an estimated $438.
Stephens Consulting first reported a position in West Pharmaceutical in Q2 2025 and held it in 1 quarter.
Stephens Consulting's West Pharmaceutical position peaked at $438 in Q2 2025.
758 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2025.

Based on Stephens Consulting's 13F filing for Q3 2025, filed 15 Oct 2025.